ImmunityBio, Inc. $IBRX Stock Holdings Lifted by Skandinaviska Enskilda Banken AB publ

Key Points

• Skandinaviska Enskilda Banken AB publ increased its IBRX stake by 347.7% to 1,324,871 shares (~$3.25M) and Vanguard now owns 27.66M shares (~$68.0M); institutional holders own 8.58% of the stock and analysts give a consensus “Moderate Buy” with a $11.80 target (market cap ≈ $8.57B).
• ImmunityBio won a conditional EU approval for ANKTIVA and signed distribution/launch partnerships in the EU and MENA to expand commercialization, but a Pomerantz LLP investor investigation and recent insider selling introduce legal and reputational risk.

Skandinaviska Enskilda Banken AB publ increased its position in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 347.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,324,871 shares of the company's stock after acquiring an additional 1,028,921 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned 0.13% of ImmunityBio worth $3,246,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Armistice Capital LLC acquired a new stake in ImmunityBio during the 2nd quarter valued at $20,497,000. Vanguard Group Inc. boosted its position in shares of ImmunityBio by 26.8% in the third quarter. Vanguard Group Inc. now owns 27,655,205 shares of the company's stock worth $68,032,000 after buying an additional 5,837,898 shares during the period. AlphaCore Capital LLC purchased a new position in shares of ImmunityBio during the second quarter valued at $7,854,000. Geode Capital Management LLC increased its holdings in shares of ImmunityBio by 34.7% in the 2nd quarter. Geode Capital Management LLC now owns 5,777,269 shares of the company's stock valued at $15,254,000 after purchasing an additional 1,487,849 shares during the period. Finally, First Trust Advisors LP purchased a new stake in shares of ImmunityBio in the second quarter worth approximately $1,448,000. Institutional investors and hedge funds own 8.58% of the company's stock.

Analyst Ratings Changes

Several analysts recently commented on IBRX shares. D. Boral Capital restated a "buy" rating and set a $24.00 price target on shares of ImmunityBio in a report on Tuesday. Piper Sandler increased their target price on shares of ImmunityBio from $5.00 to $7.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 20th. Jefferies Financial Group lifted their target price on shares of ImmunityBio from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Friday, December 12th. HC Wainwright boosted their price target on shares of ImmunityBio from $8.00 to $10.00 and gave the company a "buy" rating in a report on Monday, January 26th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of ImmunityBio in a report on Monday, December 29th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $11.80.

ImmunityBio Price Performance

NASDAQ IBRX opened at $8.70 on Friday. ImmunityBio, Inc. has a fifty-two week low of $1.83 and a fifty-two week high of $9.25. The stock's 50-day moving average is $4.48 and its two-hundred day moving average is $3.11. The firm has a market cap of $8.57 billion, a P/E ratio of -21.22 and a beta of 0.16.

Insider Activity at ImmunityBio

In other news, Director Christobel Selecky sold 25,000 shares of ImmunityBio stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $7.51, for a total value of $187,750.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Barry J. Simon sold 151,967 shares of the business's stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $7.20, for a total transaction of $1,094,162.40. Following the completion of the sale, the director owned 3,091,604 shares of the company's stock, valued at $22,259,548.80. The trade was a 4.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 226,967 shares of company stock valued at $1,531,912. Corporate insiders own 69.48% of the company's stock.

ImmunityBio News Summary

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: European conditional approval and EU commercialization push — the European Commission granted conditional marketing authorization for ANKTIVA® in combination with BCG for BCG‑unresponsive NMIBC CIS, and ImmunityBio is opening an Irish subsidiary and signing distribution deals (Accord) to support the EU launch, which meaningfully expands addressable market and revenue runway. ImmunityBio Expands Access to ANKTIVA® in EU (BusinessWire)
• Positive Sentiment: Regional commercial expansion — ImmunityBio struck a partnership with Biopharma and Cigalah Healthcare to launch ANKTIVA® in Saudi Arabia and the broader MENA region, giving the drug local distribution partners and accelerating market entry in a sizeable oncology market. ImmunityBio Partners to Launch ANKTIVA in Saudi Arabia (BusinessWire)
• Positive Sentiment: Technical momentum — the stock is showing strong technicals (reported “golden cross” and trading well above the 200‑day average), reinforcing momentum traders and institutional interest. ImmunityBio Holds Golden Cross (Benzinga)
• Neutral Sentiment: Chairman commentary and publicity — public comments linking diplomatic efforts to commercial success have generated headlines and may sustain retail interest, but they are narrative-driven rather than new financial data. Chairman Comments on Diplomacy (MSN)
• Neutral Sentiment: Corporate finance/clinical updates referenced in coverage — some articles note follow‑up clinical programs and past convertible‑note activity; these are worth monitoring for dilution or R&D progress but contain no immediate financial details. Clinical/Convertible Note Context (MSN)
• Negative Sentiment: Investor litigation investigation — Pomerantz LLP announced an investigation into ImmunityBio on behalf of investors, which introduces legal and reputational risk that could pressure the stock if it leads to claims or disclosures. Pomerantz Investigates (PR Newswire)

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.

Want to see what other hedge funds are holding IBRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ImmunityBio, Inc. (NASDAQ:IBRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.